FIELD: medicine; pharmacology.
SUBSTANCE: invention includes as active substances one or several fibrates and one or several statins or their pharmaceutically comprehensible salt, in carrier chosen from group, consisting of i) admixtures of polyethyleneglycol and poloxamer in the ratio from 2:1 to 3:1 and with the subsequent dispersion on lactose, ii) glyceryl monostearate with the subsequent spraying on lactose or on an admixture of lactose and hydroxypropymethylcellulose; and iii) polyethyleneglycol, with subsequent spraying on Aeroperl. Besides, the invention concerns firm dosed out forms including specified material and way of their obtaining.
EFFECT: possibility to establish suitable biological availability of both active ingredients at peroral insertion.
56 cl, 15 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE | 2003 |
|
RU2356549C2 |
| PRO-MEDICATION COMPOSITION FOR STRUGGLE AGAINST HEPAPATITIS C VIRUS | 2006 |
|
RU2435592C2 |
| COMPOSITION CONTAINING FENOFIBRIC ACID OR PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND CAPSULE CONTAINING COMPOSITION | 2008 |
|
RU2500398C2 |
| MEDICINAL COMBINATION COMPRISING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDINE-5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND INHIBITOR, INDUCTOR OR SUBSTRATE FOR P-450 3A4 ISOZYME | 2000 |
|
RU2233162C2 |
| NEW COMPOSITIONS OF FENOFIBRATE AND RELATED METHODS OF TREATING | 2005 |
|
RU2398577C2 |
| PHARMACEUTICAL DOSED FORM, CONTAINING POLYMER CARRIER COMPOSITION | 2009 |
|
RU2519679C9 |
| STABILIZATION OF DOSAGE FORM BASED ON SOLID OR SEMI-LIQUID LIPID BY CURING AND ADDITION OF SURFACTANT (SURFACTANTS), HAVING LOW VALUE OF HLB | 2019 |
|
RU2833036C2 |
| SOLID SOLUTION COMPOSITIONS AND USE IN CARDIOVASCULAR DISEASE | 2014 |
|
RU2674982C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES | 2012 |
|
RU2635188C2 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERLIPIDEMIA | 2017 |
|
RU2683641C2 |
